DDIT3 and diffuse large B-cell lymphoma: First, MYC activation (whether assessed by gene rearrangement, protein expression, or associated gene signatures) and CCC‐OxPhos have both been linked to poor prognosis in DLBCL patients treated with R‐CHOP [2, 3, 7, 8, 9], both behaving independently from the COO classification system [2, 3, 4].